(MENAFN- Straits Research)
Liquid Biopsy Market Size & Growth Analysis
The global liquid biopsy market size was valued at USD 12.23 billion in 2025 and is projected to grow from USD 13.61 billion in 2026 to USD 32.11 billion by 2034, registering a CAGR of 11.32% during the forecast period from 2026 to 2034. North America dominated the liquid biopsy market with a market share of 42.15% in 2025.
Liquid biopsy is a minimally invasive diagnostic technique that analyzes biomarkers found in biological fluids, primarily blood, to detect and monitor diseases. The technique commonly examines circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), cell-free DNA (cfDNA), RNA, and extracellular vesicles released into the bloodstream. Liquid biopsy is increasingly used in cancer diagnosis and management for detecting genetic mutations, identifying treatment options, monitoring treatment response, and assessing disease progression or recurrence. The market includes liquid biopsy tests, assay kits, instruments, reagents, and related diagnostic services used in hospitals, diagnostic laboratories, research institutions, and specialized oncology centers.
Liquid Biopsy Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 12.23 Billion
2026 Market Size: USD 13.61 Billion
2034 Projected Market Size: USD 32.11 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 11.32%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 42.15%
Fastest-Growing Region: Europe
Europe CAGR (2026–2034): 14.62%
Segment Insights
By Products & Services
Leading Segment: Kits and Reagents
Market Share in 2025: 48.36%
By Circulating Biomarker
Fastest-Growing Segment: Extracellular Vesicles
CAGR: 13.87% (2026–2034)
By Cancer Type Share
Leading Segment: Lung Cancer
Market Share in 2025: 32.64%
By End-User Share
Fastest-Growing Segment: Hospitals and Laboratories
CAGR: 12.94% (2026–2034)
Download a Free Sample To learn more about this report,
Liquid Biopsy Market Trends
Multi-Omics and Advanced Sequencing Expand Liquid Biopsy Capabilities
The liquid biopsy market is moving beyond conventional circulating tumor DNA analysis toward multi-omics, epigenomic profiling, advanced next-generation sequencing (NGS), and bioinformatics. These technologies can provide broader information about tumor biology, including genetic alterations, gene expression, pathway activity, and treatment resistance. The development of more comprehensive assays is strengthening the role of liquid biopsy in precision oncology and enabling clinicians and researchers to obtain deeper molecular insights from small blood samples.
In April 2026, Precede Biosciences launched Precede Bio Insight, a genome-wide liquid biopsy platform designed to infer gene expression, pathway activity, and cell states from just 1 mL of plasma. The launch demonstrates the industry's shift toward extracting broader functional and epigenomic information from liquid biopsy samples.
Liquid Biopsy Moves Toward Comprehensive and Repeatable Cancer Monitoring
Liquid biopsy is increasingly being integrated into precision oncology, treatment selection, minimal residual disease (MRD) monitoring, and disease progression assessment. Unlike tissue biopsy, blood-based testing can be repeated with relatively low patient burden, allowing clinicians to monitor molecular changes during treatment and identify emerging resistance. Increasing clinical access and the development of broader liquid biopsy panels are helping expand the technology from specialized testing toward more routine cancer management.
In May 2026, the U.S. FDA approved Guardant Health's Guardant360 Liquid CDx, expanding the test to a 100-times wider genomic footprint and integrating genomic and epigenomic insights from a blood sample. The development strengthens the use of comprehensive liquid biopsy profiling for treatment selection in patients with advanced cancer.
Liquid Biopsy Market Dynamics
Market Drivers
Growing Preference for Minimally Invasive Cancer Testing Supports Liquid Biopsy Adoption
The increasing preference for minimally invasive diagnostic procedures is supporting the adoption of liquid biopsy in cancer care. Unlike conventional tissue biopsy, liquid biopsy generally requires only a blood sample, reducing the need for invasive tissue collection and making repeat testing more practical. The ability to obtain molecular information with relatively low patient burden is particularly valuable for patients whose tumors are difficult to access or who require repeated monitoring during treatment. Growing awareness among clinicians and patients is therefore strengthening demand for blood-based cancer diagnostics.
In May 2025, Guardant Health presented updated data supporting the use of its blood-based Guardant360 CDx test for identifying actionable genomic alterations in patients with advanced cancer. The continued clinical development of blood-based genomic testing demonstrates the growing role of minimally invasive liquid biopsy in treatment decision-making.
Market Restraints
Limited Infrastructure and Awareness Restrict Liquid Biopsy Access in Emerging Markets
The availability of liquid biopsy remains uneven across developing and underdeveloped regions because advanced sequencing platforms, specialized laboratories, trained personnel, and molecular diagnostic infrastructure can be limited. Healthcare providers may also continue relying on established tissue biopsy and imaging methods because of familiarity, availability, and reimbursement considerations. Limited awareness among patients and clinicians can further delay adoption, restricting market penetration outside developed healthcare systems.
In February 2026, Illumina highlighted the continuing need to expand access to genomic testing and strengthen genomic infrastructure globally, particularly as precision medicine becomes increasingly integrated into cancer care. The industry's focus on improving access reflects the infrastructure requirements that can limit the wider adoption of advanced molecular diagnostics such as liquid biopsy.
Market Opportunity
Liquid Biopsy Creates New Avenues for Rare and Difficult-to-Diagnose Cancers
Liquid biopsy offers significant opportunities in cancers where obtaining adequate tissue samples is difficult because of tumor location, limited tumor material, or the need for repeated molecular assessment. Blood-based analysis can provide tumor-derived genetic information without requiring repeated invasive procedures, creating opportunities for earlier molecular characterization, treatment selection, and disease monitoring. As sequencing technologies become more sensitive, liquid biopsy is also gaining potential applications across cancers with limited conventional screening options.
In April 2026, Precede Biosciences launched Precede Bio Insight, a liquid biopsy platform designed to extract genome-wide information from a small plasma sample, including gene expression, pathway activity, and cell-state information. The development expands the potential of liquid biopsy beyond mutation detection and demonstrates opportunities for applying blood-based molecular analysis to a broader range of cancers.
Market Challenges
Establishing Clinical Accuracy and Standardization Across Liquid Biopsy Tests
The liquid biopsy market faces challenges related to test sensitivity, specificity, biomarker concentrations, sample handling, analytical methods, and clinical standardization. Circulating tumor DNA and other biomarkers can occur at very low concentrations, particularly in early-stage disease, making accurate detection technically demanding. Differences in testing platforms and laboratory procedures can also affect results. Establishing consistent clinical validation, regulatory acceptance, and standardized testing protocols remains essential for broader adoption in routine cancer screening and monitoring.
In May 2026, the U.S. FDA approved an expanded version of Guardant Health's Guardant360 Liquid CDx, incorporating a substantially broader genomic and epigenomic analysis from blood. The development illustrates the industry's continuing effort to improve the breadth and analytical capabilities of liquid biopsy while meeting stringent clinical and regulatory requirements.
Liquid Biopsy Market Segmentation
By Product & Services Share
The market is divided into kits and reagents, platforms and instruments, and services. The kits and reagents segment is the highest contributor to the global liquid biopsy market share, growing at a CAGR of 21.2% during the forecast period. The market for liquid biopsy kits and reagents is anticipated to grow cutting-edge products that can analyze circulating biomarkers, target enrichment, size selection, and various other tasks. The liquid biopsy instruments combine the PCR, sequencing, and real-time genetic characterization of the liquid biopsy sample under analysis. The ddPCR, produced by the American life science and clinical diagnostics company Bio-Rad Laboratories, Inc., is one illustration of such a device. On the other hand, liquid biopsy platforms offer solutions that make it possible to perform NGS and PCR on rare populations of cancer cells derived from whole blood.
Request Customization to receive a tailored report.
By Circulating Biomarkers
The market is divided into circulating tumor cells, circulating tumor DNA, and extracellular vesicles. The circulating tumor cell segment is the highest contributor to the market, growing at a CAGR of 21% during the forecast period. Circulating tumor cells (CTCs) are an essential diagnostic tool for comprehending the metastatic process and cancer progression. Poor survival rates are associated with CTCs in metastatic colon, prostate, and breast cancers. Individual CTCs may contain genetic information essential for understanding tumor biology and the metastatic process of a patient's tumor. Circulating tumor cells provide comparable or superior prognostic information compared to radiographic imaging techniques such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and ultrasound. Currently, circulating tumor cells are used as a biomarker associated with the metastatic status of cancer.
Throughout the projected period, the category with the quickest growth is anticipated to be circulating tumor DNA. The DNA from circulating tumors aids in the early detection of cancer and cancer-related mutations. It is quite effective at finding breast cancer. Consequently, it is anticipated that the increased incidence of breast cancer will accelerate the expansion of this market.
By Cancer Type
The market is divided into lung cancer, breast cancer, colorectal cancer, prostate cancer, and liver cancer. The lung cancer segment is the highest contributor to the market, growing at a CAGR of 20.4% during the forecast period. The lung cancer segment is the most significant contributor due to the high prevalence of the non-small cell lung cancer (NSCLC) type in this category, which is significantly growing globally. Further, the prostate cancer segment is anticipated to be the fastest-growing segment. This is attributed to the significantly growing prevalence of prostate cancer across the developed regions, including North America. In addition, major players in this market focus on agreements and partnerships in the prostate cancer segment.
By End-User
The market is divided into hospitals and laboratories, as well as government and academic research centers. The hospitals and laboratories segment is the highest contributor to the market, growing at a CAGR of 21.2% during the forecast period. Testing with liquid biopsies is used in hospitals and laboratories for the diagnosis, analysis, and detection of cancer. On the other hand, testing with liquid biopsies is used in government and academic research centers for research and development to understand the molecular aspects of tumors better. It is anticipated that the hospital and laboratories segment will dominate the global market. In addition, hospitals and laboratories make it possible for medical professionals to perform liquid biopsy tests to investigate the illness, better understand cancer recurrence, and determine the most effective treatment method. Consequently, it is anticipated that the hospitals and laboratories segment of the global market for liquid biopsy will generate the highest revenue of all end-user segments.
Speak to an Analyst to discuss market opportunities.
Liquid Biopsy Market Regional Overview
North America Liquid Biopsy Market Analysis
North America dominated the global liquid biopsy market in 2025, accounting for 42.15% of the market, with a market value of USD 5.15 billion. The regional market is projected to grow at a 11.84% CAGR during the forecast period. Growth is supported by the region's advanced healthcare infrastructure, high adoption of precision oncology, strong investment in cancer research, and increasing availability of liquid biopsy-based diagnostic tests. The presence of major biotechnology and molecular diagnostics companies is also accelerating the development and commercialization of blood-based cancer testing technologies.
United States Liquid Biopsy Market Insights
The United States is a major market for liquid biopsy, supported by its advanced cancer diagnostic infrastructure, strong research ecosystem, and growing adoption of precision medicine. Increasing use of circulating tumor DNA testing for treatment selection, therapy monitoring, and detection of minimal residual disease is supporting market growth. Continued investment in genomic technologies and regulatory approvals for blood-based cancer diagnostics is further strengthening the country's liquid biopsy market.
Canada Liquid Biopsy Market Insights
Canada's liquid biopsy market is supported by increasing cancer research activities, growing adoption of precision medicine, and improvements in molecular diagnostic capabilities. Healthcare institutions and research organizations are increasingly evaluating liquid biopsy for cancer detection, treatment monitoring, and genomic profiling. Growing investment in oncology research and advanced diagnostic infrastructure is expected to further support market development.
Unlock Regional Insights to access country-level data, & regional trends.
Europe Liquid Biopsy Market Analysis
Europe accounted for 28.34% of the global liquid biopsy market in 2025, with a market value of USD 3.47 billion. The regional market is expected to grow at a 14.62% CAGR during the forecast period. Growth is supported by increasing adoption of precision oncology, expanding molecular diagnostic capabilities, and rising investment in cancer research. The region's focus on early cancer detection, personalized treatment, and minimally invasive diagnostic technologies is also creating strong demand for liquid biopsy solutions.
Germany Liquid Biopsy Market Insights
Germany's liquid biopsy market is supported by its advanced healthcare infrastructure, strong oncology research capabilities, and growing emphasis on personalized medicine. Increasing adoption of genomic profiling and molecular diagnostics is creating demand for blood-based testing technologies. Research into circulating tumor DNA and other biomarkers is also expanding the potential applications of liquid biopsy in cancer treatment monitoring and therapy selection.
United Kingdom Liquid Biopsy Market Insights
The United Kingdom's liquid biopsy market is driven by strong cancer research programs, increasing adoption of precision medicine, and the development of advanced molecular diagnostics. Healthcare providers and research institutions are increasingly evaluating liquid biopsy for treatment selection, disease monitoring, and detection of residual disease. Government and research-sector investment in genomics and personalized cancer care is further supporting market growth.
Asia Pacific Liquid Biopsy Market Analysis
Asia Pacific represented 21.18% of the global liquid biopsy market in 2025, with a market value of USD 2.59 billion. The regional market is projected to grow at a 13.91% CAGR. Growth is driven by rising cancer incidence, improving healthcare infrastructure, increasing investment in molecular diagnostics, and growing awareness of minimally invasive cancer testing. Expanding precision medicine programs and greater access to advanced sequencing technologies are also creating opportunities for liquid biopsy adoption across the region.
Japan Liquid Biopsy Market Insights
Japan's liquid biopsy market is supported by its advanced healthcare system, strong cancer research capabilities, and growing focus on precision medicine. Increasing research into circulating tumor DNA and other cancer biomarkers is encouraging the development of blood-based diagnostic applications. The country's aging population and growing need for efficient cancer diagnosis and monitoring are also supporting demand for minimally invasive testing technologies.
China Liquid Biopsy Market Insights
China's liquid biopsy market is expanding alongside its rapidly developing healthcare and biotechnology sectors. Rising cancer burden, increasing investment in genomic medicine, and improvements in molecular diagnostic infrastructure are supporting demand for liquid biopsy technologies. The expansion of precision oncology and growing availability of next-generation sequencing are further creating opportunities for blood-based cancer testing.
Latin America Liquid Biopsy Market Analysis
Latin America accounted for 4.62% of the global liquid biopsy market in 2025, with a market value of USD 0.57 billion. The regional market is expected to grow at a 10.74% CAGR during the forecast period. Growth is supported by increasing cancer incidence, improving access to molecular diagnostics, and growing awareness of minimally invasive testing methods. Expansion of healthcare infrastructure and increasing adoption of precision medicine are also expected to support liquid biopsy demand.
Brazil Liquid Biopsy Market Insights
Brazil is an important market for liquid biopsy in Latin America, supported by its large healthcare system and growing focus on cancer diagnostics. Increasing cancer research, adoption of molecular testing, and demand for personalized treatment are creating opportunities for liquid biopsy technologies. Improvements in diagnostic infrastructure and growing awareness of minimally invasive cancer testing are expected to further support market expansion.
Middle East and Africa Liquid Biopsy Market Analysis
The Middle East and Africa accounted for 3.71% of the global liquid biopsy market in 2025, with a market value of USD 0.45 billion. The regional market is projected to grow at a 9.88% CAGR. Growth is supported by improving healthcare infrastructure, increasing cancer awareness, and rising investment in advanced diagnostic technologies. The expansion of oncology services and increasing adoption of molecular testing are also creating opportunities for liquid biopsy solutions.
UAE Liquid Biopsy Market Insights
The UAE's liquid biopsy market is supported by its advanced healthcare infrastructure, growing oncology capabilities, and increasing investment in precision medicine. The country's development as a regional healthcare and medical research hub is encouraging the adoption of advanced molecular diagnostic technologies. Growing demand for early cancer detection, genomic profiling, and minimally invasive monitoring is expected to support liquid biopsy market growth.
Competitive Landscape
The liquid biopsy market is highly competitive, with companies focusing on next-generation sequencing, circulating tumor DNA analysis, comprehensive genomic profiling, molecular diagnostics, and minimal residual disease testing. Key market participants include Bio-Rad Laboratories Inc., Biocept Inc., Guardant Health Inc., Illumina Inc., Hoffmann-La Roche Ltd. (Foundation Medicine Inc.), Johnson & Johnson, Laboratory Corporation of America Holdings, MDxHealth SA, QIAGEN N.V., and Thermo Fisher Scientific Inc. Companies are strengthening their positions through advanced sequencing platforms, broader biomarker panels, clinical validation, and partnerships aimed at expanding access to precision oncology.
Illumina Inc. - Leading Market Player
Illumina Inc. is a major participant in the liquid biopsy market, leveraging its next-generation sequencing (NGS) platforms and comprehensive genomic profiling technologies for circulating tumor DNA analysis. The company's portfolio supports research and clinical applications involving ctDNA, cell-free DNA, circulating tumor cells, and other cancer biomarkers. Illumina's sequencing technologies enable researchers and healthcare providers to analyze multiple genomic alterations from blood samples, supporting applications such as treatment selection, clinical trial matching, and disease monitoring.
List of Key and Emerging Players in Liquid Biopsy Market
Bio-Rad Laboratories Inc.
Biocept Inc.
Guardant Health Inc.
Illumina Inc.
Hoffmann-La Roche Ltd. (Foundation Medicine Inc.)
Johnson & Johnson
Laboratory Corporation of America Holdings
Mdxhealth SA
Qiagen N.V.
Thermo Fisher Scientific Inc.
Key Industry Developments
May 2026: Guardant Health expanded its liquid biopsy portfolio with next-generation cancer detection and monitoring solutions using advanced circulating tumor DNA (ctDNA) analysis for precision oncology applications.
March 2026: Foundation Medicine strengthened its liquid biopsy capabilities by expanding genomic profiling solutions designed to support personalized cancer treatment decisions and targeted therapies.
October 2025: Roche expanded its liquid biopsy diagnostics portfolio with advanced molecular testing technologies aimed at improving early cancer detection, treatment selection, and disease monitoring.
June 2025: Natera introduced enhanced circulating tumor DNA testing solutions through its SignateraTM platform, expanding applications in minimal residual disease monitoring and personalized oncology care.
Report Scope
Comments
No comment